The AICAR Peptide and Insulin Sensitivity

The AICAR nucleotide appears to comprise one ribose sugar, phosphate group, and adenine base. It is considered an essential nucleotide in cellular energy metabolism and may be a precursor to adenosine monophosphate (AMP). Studies suggest that AICAR may stimulate the metabolic enzyme AMP-activated protein kinase (AMPK).

Research suggests that AICAR may improve glucose tolerance, insulin sensitivity, and glucose absorption in skeletal muscle via activating AMPK. Animal studies have suggested that AICAR may enhance physical activity, and there is speculation that it may also have anti-inflammatory properties.

AICAR Peptide Research and Investigations

AICAR Peptide and Organs

Researchers speculate that AICAR may protect organs from damage caused by ischemia and reperfusion. Animal studies on myocardial ischemia-reperfusion damage have suggested that this nucleotide may decrease infarct size and enhance heart function. Key factors to reperfusion damage, including oxidative stress and inflammation, may be mitigated by AICAR’s potential to activate AMPK. [i]

Researchers hypothesize that after coronary artery bypass graft (CABG) surgery, many test subjects have problems that AICAR may mitigate. [ii] The studies conducted were placebo-controlled and double-blind. Myocardial infarction during surgery, cardiac mortality up to day 4 after surgery, and cardiac arrest, stroke, and death were all predicted to be reduced with AICAR. Further findings suggested that AICAR may decrease the need for ventricular-assistance devices in subjects with severe surgical heart failure.

AICAR’s protective properties may extend beyond the liver. The action of the AMPK activator AICAR on a rat model of ethanol-induced hepatic steatosis was studied. [iii] The research suggested continuous ethanol feeding led to a histologically and biochemically fatty liver, but AICAR appeared to mitigate this change. One study suggested that AICAR may inhibit triglyceride production by decreasing rats’ hepatic SREBP-1c and FAS expression.

AICAR Peptide and Insulin Sensitivity

oxide appeared to mediate the improvement in blood flow as an inhibitor of endothelial NO synthase appeared to reduce the improvement. [x]

More investigation is required to explore its potential in scientific research, and these studies must continue. Only academic and scientific institutions are allowed to use AICAR peptides. If you are a licensed professional interested in buying peptides for your clinical studies, visit this website.

Please note that none of the items mentioned are approved for human or animal ingestion. Laboratory research compounds are only for in-vitro and in-lab use. Any kind of physical introduction is illegal. Only authorized professionals and working scientists may make purchases. The content of this article is intended only for educational purposes.

References:

[i] Cieslik, K. A., Taffet, G. E., Crawford, J. R., Trial, J., Mejia Osuna, P., & Entman, M. L. (2013). AICAR-dependent AMPK activation improves scar formation in the aged heart in a murine model of reperfused myocardial infarction. Journal of molecular and cellular cardiology, 63, 26–36. https://doi.org/10.1016/j.yjmcc.2013.07.005

[ii] Mangano D. T. (1997). Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA, 277(4), 325–332.

https://doi.org/10.1001/jama.277.4.325

[iii] Tomita, K., Tamiya, G., Ando, S., Kitamura, N., Koizumi, H., Kato, S., Horie, Y., Kaneko, T., Azuma, T., Nagata, H., Ishii, H., & Hibi, T. (2005). AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats. Alcoholism, clinical and experimental research, 29(12 Suppl), 240S–5S. https://doi.org/10.1097/01.alc.0000191126.11479.69

[iv] de Laat, M. A., Robinson, M. A., Gruntmeir, K. J., Liu, Y., Soma, L. R., & Lacombe, V. A. (2015). AICAR administration affects glucose metabolism by upregulating the novel glucose transporter, GLUT8, in equine skeletal muscle. Veterinary journal (London, England: 1997), 205(3), 381–386. https://doi.org/10.1016/j.tvjl.2015.05.018